Clinical Trials Logo

Clinical Trial Summary

This is prospective, multicenter, randomised phase III trial among women with endometrial cancer with high-intermediate risk features to investigate the role of an integrated clinicopathological and molecular risk profile to determine if participants should receive no adjuvant therapy, vaginal brachytherapy or external beam radiotherapy based on a favourable, intermediate or unfavourable profile as compared to standard adjuvant vaginal brachytherapy.


Clinical Trial Description

Adjuvant therapy for women with endometrial cancer has increasingly been tailored to prognostic factors to prevent overtreatment and select those women for adjuvant treatment who will have a clinically relevant reduction of the risk of relapse by the adjuvant treatment. Risk profiles have traditionally been based on clinicopathological factors such as age, stage, grade, LVSI and depth of invasion. Newer, both molecular-genetic (the cancer genome atlas subgroups) or immunohistochemistry-based (L1-CAM) risk factors have become available which are strongly related to outcomes and risk of cancer spread. In a comprehensive analysis of the PORTEC-1 and-2 biobank an integrated clinicopathological and molecular risk profile was determined which separated the current high-intermediate risk group of endometrial cancer in 3 separate groups (favourable, intermediate or unfavourable) with clearly separated outcomes, which is now prospectively tested in the clinic to determine adjuvant treatment. This is the first randomised trial using the molecular risk factors to assign adjuvant treatment for women with stage I-II high-intermediate risk endometrial cancer. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03469674
Study type Interventional
Source Leiden University Medical Center
Contact
Status Active, not recruiting
Phase Phase 3
Start date June 10, 2016
Completion date December 31, 2028

See also
  Status Clinical Trial Phase
Not yet recruiting NCT04046185 - Programmed Death-1(PD-1) Inhibitor Combined With Progesterone Treatment in Endometrial Cancer Early Phase 1
Not yet recruiting NCT06278857 - SATELLITE Study (feaSibility sAfeTy Efficacy dostarLimab earLy-stage defIcient endomeTrial cancEr) Phase 2
Recruiting NCT04792749 - Clinical Effects of Metformin on Fertility-sparing Treatment for Early Endometrial Cancer Phase 3
Completed NCT04972682 - [SENTRY] Tailoring Postoperative Management Through Sentinel Lymph Node Biopsy in Low- and Intermediate-Risk Endometrial Cancer N/A
Recruiting NCT05179447 - PROfiling Based Endometrial Cancer Adjuvant Therapy N/A
Recruiting NCT04073706 - Sentinel Node Biopsy in Endometrial Cancer Phase 3
Recruiting NCT04291612 - Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease
Recruiting NCT06417736 - Prospective Study for Endometrial Carcinoma and Hyperplasia in Childbearing-age Women N/A
Recruiting NCT04839614 - Concurrent Laparoscopic Hysterectomy and Weight Loss Surgery in Obese Patients With Endometrial Carcinoma or Endometrial Intraepithelial Neoplasia N/A
Completed NCT03580421 - Cost-utility of Ambulatory Surgery in the Management of Endometrial Cancer(AMBU-ENDO) N/A